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(8.8% YS 42.7%). target lesion revascularizatron (4.7% vs 8.3%) and MACE (8.6% vs 
23.1%). Eight pts in the overlap SES group had Res within the stent margins; one case 
was subacute stent thrombosis, one case was focal and not at the overlap region, one 
had diffuse Res (3 undersized stents after severe dissection), and the five remaining 
cases had focal Ras within the overlap region. Conclusions Overlapping SES vs. CS in 
the SIRIUS trial was associated with (1) infrequent adverse clinical outcomes (death, MI, 
stent thrombosis, or aneurysms), (2) maintained striking improvement for SES in all effi- 
cacy measures, and (3) the site of SES Res was usually withrn the stent at the overlap 
region. Factors such as vessel tortuosity, local flow disturbances, drug dosing effects or 
stent-edge incomplete apposition may contribute to this apparent increased overlap zone 
Res. which may be partially resolved with the use of longer single SES and IVUS guid- 
ance. 
(@270 days) SES (N=533) Control (N=525) P-value 
Death 0 9% 0.6% ns 
Ml (all) 2.8% 3.2% “s 
Stent thrombosis (all) 0.4% 0.8% “s 
TLR 4.1% 16.6% <0.001 
TVR (non-TL) 3.2% 4.8% ns 
MACE 7.1% 18.9% <O.OOl 
NF 8.6% 21 .O% <O.OOl 
Table I 
TLR = target lesion revascularization, TVR = target vessel revascularization, MACE = 
mafor adverse cardiac events, TVF = target vessel failure 
1o:oo a.m. 
805-4 Late Incomplete Stent Apposition Following Sirolimus- 
Eluting Stent: Serial Quantitative Intravascular 
Ultrasound Analysis From the SIRIUS Trial 
Junva Ako, Yoshihiro Merino, Yasuhiro Honda, Shinjo Sonoda. Mitsuyasu Terashima, Ali 
Hassan, Martin 6. Leon, Jeffrey W. Moses, Steve Osterle, Charles L. Brown, Donald S. 
Bairn, Paul G. Yock, Peter J. Fitzgerald, the SIRIUS Investigators, Stanford University, 
Stanford, CA, Lenox Hill Hospital, New York, NY 
Background: Stent incomplete apposition (IA) at follow-up is reported in drug-eluting 
stents. The aim of this study was to clarify the morphometric IVUS characteristics of late 
IA as compared with persistent IA following sirolimus-eluting stents (SES) vs bare metal 
stems (EMS). 
Methods: IVUS data were obtained from SIRIUS, a prospective, randomized, multicenter 
trial. IA was defined as z-1 struts separated from vessel wall with evidence of blood 
speckle behind the struts. The maximal stenfflumen gap, maximal axial length, and arc 
degrees of incompletely apposed struts were quantified. IA index was defined as total 
lumen area divided by lumen area within the stent. Persistent IA was considered present 
when IA was observed at both baseline and &month follow-up. Late IA was defined as 
new IA detected only at follow-up. 
Results: Of 130 serial cases, there were 19 follow-up IA segments in 17 patients (BMS 6, 
SES 11) available for quantitative analysis. While persistent IA was observed in both 
groups (EMS 6, SES 4) late IA was seen only in SES. AVessel area was significantly 
larger in late IA than persistent IA (~~0.05) and 3 late IAs showed pathologtc positive 
remodeling (z-20% increase in vessel area compared to baseline). All persistent IAs were 
located at stent edges, whereas 77% of late IAs occurred at single or multiple mid-stent 
segments (~~0.05). 
Conclusions: The characteristic morphometric findings of late IA following SES may sug- 
gest different vessel wall biology of this phenomenon compared to persistent IA. 
persistent IA BMS persistent IA SES late IA SES 
(n=6) (n=4) (It=9) 
Gap, mm2 0.36+0.17 0.40*0.12 0.69eO.33 
Arc, * 107t22.5 97*14.0 145*53.1 
Length, mm 1.9eO.65 2.8il.7 4.2t3.4 
Follow-up lumen area, mm2 8.3+2.5 9.&l .4 11.0*2.r3 
Follow-up vessel area, mms 1 WA7.3 17.0r2.5 l&9+3.6 
Avessel area, mm2 -0.007+0.61 0.34*0.&3 2.6il .O 
IA index l.lt0.07 1.1*0.02 1.3*0.36 
10:15 a.m. 
805-5 Do Overlapping Multiple Sirolimus-Eluting Stents 
Impact Angiographic and Clinical Outcomes? Insights 
From the SIRIUS Trial 
Giora Weisz, Jeffrey W. Moses, Jeffrey J. Popma, Greg Mishkel. Robert L. Wilensky, 
Barry Cohen, Hooman Madyoon. David Roberts, Martin B. Leon, Lenox Hill Hospital 
Heart and Vascular Institute of New York and Cardiovascular Research Foundation, New 
York, NY 
Background: Although previous clinical studies have demonstrated a dramatic reduction 
in subsequent restenosis (Res) after wolimus-elutrng stent (SES) implantation, links IS 
known about the impact of overlapping multrple stents on angiographic and clinical out- 
comes.Methods: In the randomized, double-blind SIRIUS trial, in longer lesions or to 
treat edge dissections, multiple overlapprng stents were implanted tn 33% of the SES pts 
(n=l76) and in 32% of the control bare stent (CS) pts (n=l68). Clinical and angiographlc 
findings, including the contribution of the overlap region to Res, were assessed. Results: 
Overlap SES and CS pts had similar reference vessel diameter (2.77 vs 2.80 mm), lesion 
length (18.2 vs 18.1 mm), pretreatment minimal luminal diameter (0.93 vs 0.94 mm), 
stent length (28.3 vs 27.8 mm), and stent overtap-segment length (4.6 vs 4.1 mm). There 
were no drfferences in safety outcomes Including In-hospital MACE (4.5% vs 4.2%) sub- 
acute stent thrombosis (I pt in each group, 0.6%) late stent thrombosis (none), and 
aneurysms (none). Anglographic and clinical efficacy were sfgnificantly better (pcO.001) 
in the SES vs. CS pts: in-lesion late loss (0.20 vs 0.93 mm), in-lesion binary restenosis 
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808-l Mobilized Bone Marrow Stem Cells Accelerate 
Reendothelialization, Reduce Vascular Inflammation, 
and Prevent Restenosis After Intravascular Radiation 
Hvun-Jai Cho. Hyo-Soo Kim, Dae-Hee Kim, Seil Oh, In-Ho Chae, Byung-Hee Oh, 
Myoung-Mook Lee, Young-Bae Park, Yun-Shik Choi, Seoul National University College 
of Medicine, Seoul, South Korea, Clinical Research Institute, Seoul National University 
Hospital, Seoul, South Korea 
Background: Stem cell therapy may provide new possibilities for the treatment of vascu- 
lar disorders. We investigated a role of mobilized stem cell in the healing process after 
intravascular radiation, the condition of few replicating endothelial cells in adjacent area. 
Methods: 1% cholesterol diet fed male New Zealand White rabbits with injured iliac 
artery were divided into two groups. The GM-CSF group (n=l5) received rhGM-CSF 
(6Qgiday) daily for 1 week, beginning 7 day before injury. Control group (n=lr3) received 
human albumin. One iliac artery was subjected to intravascular radiation via ‘ssRe-bal- 
loon and the contralateral iliac artery to balloon angioplasty control. Morphometry and 
immunohistochemistry were done. Peripheral blood mononuclear cells (MNCs) were iso- 
lated from blood just before vessel harvest, analyzed FACS and cultured for 4 weeks. 
Results: In control group, intravascular radiation therapy reduced neointimal hyperplasia 
(0.09*0.03 vs 0.26+0.11 rnd, P<O.Ol) but delayed reendothalialization and promoted 
inflammatory cell infiltration. After GM-CSF pretreatment, reendothelialization index 
(defined as CD31 stained endoluminal perimeter) recovered to al*13 % (n=7), whereas 
30+11 % in the control radiatron group (n=9) (PcO.01) and RAM1 l-positive cell (mac- 
rophage) infiltration reduced in media at 14 days. (12+7 vs 29+10 %, PcO.01) Also, addi- 
tional significant reduction in neointimal thickening was observed. (0.04+0.01 vs 
0.09iO.03 mm’, P<O.Ol) FACS analysis showed that 24% of MNCs were positive for 
CD31 and 13% positive for CD34 in the GM-CSF group but all negative in the control 
group. Cultured cells were assayed with costainrng with Dil/acLDL and FITC-confugated 
BS Lectin as endothelial progenitor cells, also double positive stained cell count was srg- 
nificant higher in GM-CSF group. (33*15 vs 6+4 imr?, 2 weeks; 446ilOl vs 5&29 / 
mn-?, 4 weeks after culture, P~o.01) 
Conclusions: GM-CSF pretreatment mobilizes stem cells, accelerates reendothelializa- 
tion and reduces inflammatory cells infiltration after intravascular radiation therapy, which 
suggests that stem cell therapy is a promising strategy for enhanong vascular healing 
process after angioplasty. 
9:30 a.m. 
808-2 Activation of Peroxisome Proliferator-Activated 
Receptor and Gamma Inhibits Neointimal Formation in a 
Diabetic Rat Carotid Artery Injury Model 
Kai Wanq Liming Fan, Zhongmin Zhou, Farhad Forudi, Xiaorong Zhou, A. Michael 
Lincoff, Eric J. Topol, Marc S. Penn, The Cleveland Clinic Foundation, Cleveland, OH 
Background: Peroxisome Prokferator-Activated Receptor y (PPARy) is member of the 
nuclear receptor superfamily of ligand-dependent transcription factors. Thiazolidinedi- 
ones, which are anti-diabetic agents and high-affinity ligands for PPARy, have been 
shown to inhibit the growth of vascular smooth muscle cells. In this study, the role of 
PPARy on neointimal formation was studied in a diabetic rat carotid artery injury model. 
Methods and Results: Balloon injury of carotid artery was performed in the Zucker fat 
rats (diabetic) and lean rats (non-diabetic) using the standard method. In treatment 
groups, rosiglitazone (20mgikglday) PPARy agonist, was grven orally 1 week before 
injury through the 21 days follow-up. The animals were sacrificed after 21 days, and mor- 
ohometric analvsis was performed. Lioids and alucose assav was DerfOrmed at baseline _ 
and 21 days. Neorntimal formation was significantly decreased by the administration of 
roskalitazone. but onlv in the diabetic rat cohort (Table). There was no difference of lioids 
and glucose levels between baseline and 21 days in the diabetic rats. Conclusion: The 
activation of PPAW inhibits neointimal hyperplasia in a diabetic rat carotid arlery injury 
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model, highlighting this receptor’s potential role in the prevention of restenosis in the dia- 
betic patients.. 
Table. Morphometric Data 
Zucker fat rats Zucker lean rats 
Placebo Treatment Placebo Treatment 
(n=12) (n=6) (n=lO) (n=7) 
Luminal area (mm2) 0.15+0.05 0.22+0.06’ 0.21iO.04 0.23*0.04 
Neointimal Area (IA, mn+) 0.21+0.05 0.15iO.05’ 0.14-tO.06 0.12*0.03 
Medial Area (MA, mr$) 0.10*0.01 0.10*0.01 0.11*0.03 0.10+0.01 
External Elastic Lamina (mm?) 0.45kO.05 0.47*0.05 0.46+0.05 0.44+0.04 
IA/MA 2.10i0.47 1.43i0.47’ 1.21~0.41 1.21*0.30 
* P-z 0.05 when compared with placebo. 
9:45 a.m. 
808-3 Vascular Injury Induces Expression of Periostin: A 
Novel Vascular Extracellular Matrix Protein via the Pl3- 
Kinase-MAP Kinase Pathway 
Guohono Li, David Wang, Yiu-Fai Chen, Suzanne Oparil, University of Alabama at 
Birmingham, Birmingham, AL 
Periostin (PN, also known as osteoblast-specific factor-2, OSF2), is a novel cell adhesion 
protein secreted by osteoblasts and osteoblast-like cell lines that has been described in 
the embryonic heart but not in adult cardiovascular tissues. Based on previous findings 
from our laboratory and others that extracellular matrix (ECM) proteins such as 
osteopontin (OPN) play an important role in vascular remodeling following endoluminal 
injury, we tested the hypotheses that PN is expressed in arteries in the setting of acute 
vascular injury and explored the signaling mechanisms involved using rat aortic smooth 
muscle cells (RASMCs) in vitro. Sprague Dawley rats (male, lo-wk old) were subjected 
to balloon injury of the right carotid artery and sacrificed at 3 days (n=7) and 7 days (n=6) 
post injury. Uninjured right carotid arteries from sham-operated rats were used as con- 
trols (n = 6). PN and OPN mRNA expression was analyzed by Northern blot. PN and 
OPN mRNA were undetectable in uninjured control vessels but increased post injury, 
with a peak at 3 days. PN mRNA expression in cultured RASMCs was robustly stimu- 
lated by growth factors (10 @ml of FGF-1, PDGF-66) and angiotensin II (100 nM), (2.5- 
, 2-, and 3.2- fold increases), respectively. This stimulatoiy effect was completely inhib- 
ited by pretreatment with either the PI3 kinase inhibitor (LY294002, 10 uM) or the MAP 
kinase inhibitor (U0126, 5 uM). In contrast, OPN mRNA expression was not affected by 
LY294002 and only partially (50%) inhibited by UO126 This study provides a first demon- 
stration that vascular injury induces PN expression, likely via the PIS-kinase- MAP kinase 
pathway, suggesting a contribution of this novel ECM protein to neointima formation fol- 
lowing vascular injury. 
IO:00 a.m. 
808-4 Systemic Markers of Inflammation Do Not Predict 
Coronary In-Stent Restenosis in Stable Angina Patients 
Treated With HMG CoA Reductase Inhibitors 
Abuzeid Gomma. Gideon Hirschfield June Gallimore, Gordon Lowe, Mark Pepys, Kim 
Fox, National Heart and Lung Institute and Royal Brompton Hospital. London, United 
Kingdom, Royal Free and University College Medical School, London, United Kingdom 
Introduction: C-reactive protein (CRP), serum amyloid A protein (SAA), and interleukin- 
6 (IL-6) can predict coronary r&stenosis following angioplasty and stent deployment. In 
view of the anti-inflammatory activity of HMG CoA reductase inhibitors (statins), we 
reviewed this association in statin treated stable angina patients, undergoing angioplasty 
and stenting. Methods: We investigated this association in 162 stable angina patients, in 
whom 152 underwent elective coronary artery stenting and a further 30, diagnostic 
angiography alone. of the patients as a whole, 60% were receiving HMG CoA reductase 
inhibitors, At 6 months 133 stented patients were restudied and the target lesions quanti- 
fied. Baseline and serial CRP, SAA and IL-6 values were measured by high sensitivity 
immunoassays; values are reported as medians. Results: The binary restenosis rate at 
follow-up was 33.6%. There were no significant differences in values of CAP, SAA or IL- 
6 between patients with or without in-stem restenosis. Patients with pre-procedural val- 
ues of CRP. SAA or IL-6 greater than the median, continued to have elevated values at 
follow up.Pre-procedural values of CRP and SAA did not differ between patients under- 
going angiography alone or angioplasty plus stenting (CRP: 3.7mg/l vs 3mg/l; SAA: 
4.lmgIt vs 3.5mgIl). despite a small difference in values of IL-6 (1.92pg/ml YS 2.76pg/ml, 
PzO.02). Pre-procedural values of CRP, but not SAA or IL-6, correlated positively with 
BMI (P=O.Ol). Higher values of CRP (5.95 mg/l vs 2,95mg/l. PzO.09) and SAA (4.9mg/l 
vs amgil, PzO.026) were seen in women. while smokers or ex-smokers had elevated val- 
ues of CRP (365mg/l vs 2.15mgA. P<O.OOi). Conclusion: Pm- or peri-procedural vai- 
ues of CRP, SAA or IL-6, are not associated with coronary in-stent restenosis in stable 
angina patients in contrast to previous report in patients predominantly with unstable 
angina. In addition to differences in pathobiology between stable and unstable coronary 
syndromes, the widespread use of statins with anti-inflammatory activity, reflected by 
suppression of CRP production, may mask the association. 
IO:15 a.m. 
808-5 Obligate Role of Macrophage Colony-Stimulating Factor 
for the Development of Neointimal Thickening 
Following Arterial Injury 
Trioathi B. Raiavashisth. Ming Liu, Hiroyuki Tanaka, Jagannath Tripathi, Pinky Tripathi, 
Arthur Loussararian, Peter Libby, Hiroyasu Uzui. Aatish Kumar, Terence M. Doherty, 
Bojan Cercek, Sanjay Kaul, Prediman K. Shah, Cedars-Sinai Medical Center, Los 
Angeles, CA, Brigham &Women’s Hospital and Harvard Medical School, Boston, MA 
Although evidence suggests that macrophage-colony stimulating factor (M-CSF) panici- 
pates critically in atherosclerosis, little is known about the role of M-CSF in the develop- 
ment of neointimal hyperplasia following mechanical vascular injury. We examined the 
expression of M-CSF and its receptor, c-fms, in rodent and rabbit models of arterial 
injury. Injured rat carotid arteries expressed 3- to lo-fold higher levels of M-CSF and c- 
fms mRNA within 24 hours following balloon injury as compared to uninjured arteries. 
The levels of mRNA paralleled the expression of immunoreactive M-CSF and ofms pro- 
tein. In the rabbit, M-CSF protein expression was greatest in neointimal smooth muscle 
cells (SMCs) post injury, with some expression also observed in medial SMCs. M-CSF- 
positive neointimal and medial SMCs exhibited markers of proliferation. At 30 days post 
injury, neointimal SMCs in the adjacent healed area near the border between injured and 
uninjured zone lost both proliferative activity and overexpression of M-CSF. The pres- 
ence of induced M-CSF and cfms expression correlated with the initiation of SMCs pro- 
liferation. We, therefore, investigated in vitro the effect of exogenous M-CSF on the 
proliferation of cultured human aortic SMCs (HASMCs). Recombinant human M-CSF 
stimulated an increase in the incorporation of PH] thymidine in HASMCs in a concentra- 
tion-dependent manner, and this effect was inhibited by a rat monoclonal antibody spe- 
cific to the cell surface epitope of human c-/rns. The presence of c-fms transcript and 
protein in HASMCs was demonstrated by Northern and Western blot analysis, respec- 
tiiely To test further the role of M-CSF in viva, we induced arterial injury by placing a 
periadventitial cuff around the carotid arteries in compound mutant mice lacking apolipo- 
protein (ape) E and M-CSF. Homozygous loss of M-CSF (the op mutation) abolished the 
neointimal hyperplastic response to arterial injury in apo E knockout mice. Local delivery 
of M-CSF to the injured artery restored neointimal proliferation. Taken together, our 
experimental studies suggest a critical role for M-CSF signaling through c-tmsfor neoint- 
imal thickening in response to arterial injury. 
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813-l Elevated Baseline C-Reactive Protein is Associated 
With Increased Risk of Death and Myocardial Infarction 
at One Year Following Percutaneous Coronary 
Intervention 
Joel P. Reginelfi, David S. Lee, Derek P. Chew, Ivan P. Casserly, Kent Dauterman, Kent 
W. Dauterman, Stephen G. Ellis, The Cleveland Clinic Foundation, Cleveland, OH 
Background: An elevated baseline C-reactive protein (CRP) prior to PCI has been asso- 
ciated with worse outcomes at 30 days; however, the longer term prognostic significance 
of an elevated value is not well established. We sought to determine if an elevated base- 
line CRP prior to PCI impacts long-term outcomes at l-year. Methods: Using a single- 
center intewentional registry database, we identified 1644 consecutive PCI patients in 
whom baseline pm-procedural CRP values were prospectively collected. Patients were 
divided into 4 quartiles (Q) based on CRP value (in mg/dl): 01<0.16, Q2=0.16-0.40, 
Q3=0.41-1.10, and Q471.10. One year outcome data, including death and Ml, were col- 
lected on all oatients. Results: For each increasino ouartile of CRP. there was a sionifi- 
1  
cantly increased risk of death (Figure) and death/Ml at one year (death-X2=66, p<O.OiOl; 
death/MI-&43. ocO.0001). Usina a Cox orooortional hazards model to adiust for con- 
I” 
founding by age, lesion score, LVEF. ACS, renal insufficiency, BMI, and statin therapy, 
baseline CRP remains a significant predictor of l-year death or Ml (HR=1.24 [CI=l.OB- 
